Canada Pension Plan Investment Board Arrowhead Pharmaceuticals, Inc. Transaction History

Canada Pension Plan Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $141,729 - $258,111	-5,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $202,062 - $356,847	5,100 New	5,100 $235,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $62,933 - $91,586	-1,078 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $66,997 - $97,364	1,078 New	1,078 $89,000
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $55,276 - $81,513	-901 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$43.82 - $85.37 $39,481 - $76,918	901 New	901 $69,000
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $514,755 - $794,685	-15,500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $379,157 - $628,107	14,516 Added 1475.2%	15,500 $669,000
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $1.23 Million - $3.76 Million	-59,630 Reduced 98.38%	984 $28,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.17 Million - $3.04 Million	41,614 Added 219.02%	60,614 $3.85 Million
Q2 2019 Aug 12, 2019	BUY	$17.43 - $28.82 $331,170 - $547,580	19,000 New	19,000 $504,000

296

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.97B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.